Novo Nordisk Hits New 1-Year High at $42.97 (NVO)
Novo Nordisk (NYSE:NVO)’s share price reached a new 52-week high on Monday , Stock Ratings News reports. The company traded as high as $42.97 and last traded at $42.76, with a volume of 750,440 shares traded. The stock had previously closed at $42.85.
A number of research firms have recently commented on NVO. Analysts at Zacks downgraded shares of Novo Nordisk from an “outperform” rating to a “neutral” rating in a research note to investors on Monday. They now have a $45.00 price target on the stock. Analysts at Swedbank upgraded shares of Novo Nordisk from a “neutral” rating to a “buy” rating in a research note to investors on Friday, January 31st. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $487.50.
The stock’s 50-day moving average is $38.17 and its 200-day moving average is $35.27. The company has a market cap of $113.9 billion and a price-to-earnings ratio of 26.40.
Novo Nordisk (NYSE:NVO) last announced its earnings results on Tuesday, January 28th. The company reported $0.42 EPS for the quarter. On average, analysts predict that Novo Nordisk will post $1.88 earnings per share for the current fiscal year.
Novo Nordisk A/S is a Denmark-based health care company. It also focuses within areas, such as haemostasis management, growth hormone therapy and hormone replacement therapy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.